中国实用妇科与产科杂志

中国实用妇科与产科杂志

• 论著 • 上一篇    下一篇

八聚体结合转录因子4与蛋白激酶B1基因在卵巢浆液性肿瘤组织表达及耐药相关性研究

史聪1，王敏1，朱彦丽2，闫效宇1   

  1. 作者单位：1.中国医科大学附属盛京医院妇产科，辽宁 沈阳110004；2.沧州市中心医院妇产科，河北 沧州061001
  • 出版日期:2014-10-02 发布日期:2014-09-28
  • 通讯作者: 王敏

The expression of OCT4 and AKT1 in ovarian serous tumor and their correlation with drug resistance of chemotherapy.

SHI Cong**，WANG Min** ,ZHU Yan-li, YAN Xiao-yu*..   

  1. *Departrment of Obstetrics and Gynecology，Shengjing Hospital Affiliated to China Medical University，Shenyang 110004，China
  • Online:2014-10-02 Published:2014-09-28

摘要：

目的 研究八聚体结合转录因子4（OCT4）和蛋白激酶B1（AKT1）基因在卵巢浆液性肿瘤组织中的表达，探讨两者之间相关性及在化疗耐药中发挥的作用。 方法 全部病例来自中国医科大学附属盛京医院2004年1月至2010年10月。采用免疫组织化学SP法对67例卵巢浆液性腺癌（化疗耐药30例，化疗敏感37例）、10例卵巢交界性浆液性囊腺瘤、10例卵巢良性浆液性囊腺瘤和10例正常卵巢组织中OCT4和AKT1的表达情况进行检测。 结果 OCT4的阳性表达率在卵巢浆液性腺癌、卵巢交界性浆液性囊腺瘤、卵巢良性浆液性囊腺瘤和正常卵巢组织中依次降低，差异具有统计学意义（P=0.002）；在耐药组和敏感组的阳性表达率分别为83.33%和45.95%，差异有统计学意义（P=0.002）。AKT1蛋白在正常组、良性组、交界性组和恶性组的阳性表达率分别为0、40.00%、70.00%、62.69%，差异具有统计学意义（P=0.001）；在耐药组和敏感组的阳性表达率分别为76.67%和51.35%, 两组比较，差异有统计学意义（P=0.033）。OCT4蛋白与卵巢浆液性癌临床病理因素无关，AKT1蛋白与卵巢浆液性癌的临床分期呈正相关（P<0.05）。OCT4与AKT1蛋白在耐药组中呈正相关（r=0.388，P=0.034）；在敏感组无明显相关性（r=0.246，P=0.142）。

关键词: 卵巢肿瘤, 化疗耐药, 八聚体结合转录因子, 蛋白激酶B1, 免疫组织化学

Abstract:

Abstract： Objective To study the expression of OCT4 and AKT1 in ovarian serous tumor and their correlation with drug resistance of chemotherapy.Methods From Shengjing Hospital of China Medical University between January 2004 and October 2010，67 cases of ovarian serous cystadenocarcinoma were selected(30 cases resistant,37 cases sensitive)，10 cases of normal ovarian tissues，10 cases of ovarian benign cystadenoma and 10 cases of ovarian serous cystadenoma for test. The OCT4 and AKT1 were tested by immunohistochemistry. Results The positive rates of OCT4 in normal group, benign group, borderline group and malignant group were 0，40.00%,50.00% and 62.69%,the differences being significant(P=0.002); in drug resistance group and sensitive group they were 83.33%and 45.95%，the differences being significant(P=0.002). The positive rates of AKT1 in normal group, benign group, borderline group and malignant group were0,40.00%,70.00% and 62.69%,the differences being significant(P=0.001); in drug resistance group and sensitive group were they 76.67% and 51.35%，the differences being significant(P=0.033). The expression of OCT4 didn’t correlate with any clinicopathologic factors, but AKT1 correlated with clinical stage（P<0.05）. A positive correlation was found between the expression of OCT4 and AKT1 in drug resistance group（r=0.388,P=0.034） but not in sensitive group（r=0.246,P=0.142）. Conclusions OCT4 and AKT1 are probably involved in early carcinogenesis of ovarian serous cystadenocarcinoma and risk factors for drug resistance.

Key words: ovarian serous cystadenocarcinoma, resistance；OCT4 ；AKT1；immunohistochemisty

中图分类号: